-
Product Insights
Leiomyosarcoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Leiomyosarcoma is an aggressive soft tissue sarcoma derived from smooth muscle cells typically of uterine, gastrointestinal or soft tissue origin. Symptoms include a noticeable lump or swelling, pain, if it presses on nerves or muscles and a blockage in the stomach or intestines or gastrointestinal bleeding if the tumor is located in the abdomen or digestive tract. Predisposing factors include age, chemical exposure and radiation exposure. The Leiomyosarcoma - drugs in development research report provides a comprehensive overview on the...
-
Product Insights
Fibrosarcoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Fibrosarcoma is a malignant tumor derived from fibrous connective tissue. Symptoms include local pain, local swelling, local warmth, dilated blood vessels pain and swelling of the bone, pathological fractures, neurological and vascular changes. The Fibrosarcoma - Drugs in Development research report provides a comprehensive overview on the therapeutics under development for Fibrosarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action...
-
Product Insights
Synovial Sarcoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Synovial sarcoma is a soft tissue tumor occurring in the biphasic or monophasic type and consisting of epithelial and/or spindle cell components. Symptoms include swelling, mass that may or may not be accompanied by pain and limping or difficulty using legs, arms, hands or feet. The Synovial sarcoma - drugs in development research report provides a comprehensive overview on the therapeutics under development for Synovial sarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route...
-
Product Insights
Cancer Anorexia-Cachexia Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
The Cancer Anorexia-Cachexia Syndrome pipeline market report provides a comprehensive overview of the therapeutics under development for Cancer Anorexia-Cachexia Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cancer Anorexia-Cachexia...
-
Product Insights
Thyroid Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Thyroid Cancer Pipeline Drugs Market Report Overview Thyroid cancer is a cancer that starts in the thyroid gland. Symptoms include a lump that can be felt through the skin on the neck, difficulty swallowing, pain in the neck and throat, and swollen lymph nodes in the neck. Predisposing factors include females, high levels of radiation, and inherited genetic syndromes. Treatment includes surgery and thyroid hormone therapy. The Thyroid Cancer pipeline market report provides a comprehensive overview of the therapeutics under...
-
Product Insights
Hypopharyngeal Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
The Hypopharyngeal Cancer pipeline market report provides a comprehensive overview of the therapeutics under development for Hypopharyngeal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hypopharyngeal Cancer and features...
-
Product Insights
Malignant Mesothelioma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
The Malignant Mesothelioma pipeline market report provides a comprehensive overview of the therapeutics under development for Malignant Mesothelioma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Malignant Mesothelioma and features...
-
Sector Analysis
Brain Cancer - Epidemiology Forecast to 2030
The diagnosed incident cases of brain cancer were 121,646 cases in the eight major markets (8MM) in 2020 and are expected to achieve an AGR of more than 2% during 2020-2030. The type and severity of a brain tumor are defined by the cells from which the tumor originated, as well as by the proliferative potential of the abnormal growth. Only those tumors that are malignant are designated as cancer. The brain cancer market research report provides an overview of...
-
Sector Analysis
Chronic Myeloid Leukemia: Epidemiology Forecast to 2030
In the eight major markets (8MM), the diagnosed incident cases of CML are expected to increase from 15,515 cases in 2020, at an Annual Growth Rate (AGR) of more than 1%. In 2030, the US will have the highest number of diagnosed incident cases of CML in the 8MM, whereas Canada will have the fewest diagnosed incident cases. In the 8MM, the 20-year diagnosed prevalent cases of CML are expected to increase from 142,404 cases in 2020 at an AGR...
-
Product Insights
Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players
Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma), complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.